Tech Company Financing Transactions

Cour Pharmaceuticals Funding Round

Cour Pharmaceuticals closed a $105 million Series A funding round on 1/30/2024. Backers included Alpha Wave Ventures, Lumira Ventures and Angelini Ventures.

Transaction Overview

Company Name
Cour Pharmaceuticals
Announced On
1/30/2024
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series A
Investors

Alpha Wave Ventures (Lead Investor)

Lumira Ventures (Lead Investor) (Benjamin Rovinski)

Angelini Ventures

Bristol Myers Squibb

JDRF T1D Fund

Pfizer Venture Investments

Roche Venture Fund (Simon Greenwood)

Proceeds Purpose
The proceeds will enable COUR to advance multiple, wholly owned product candidates that leverage the company's immune tolerance platform, including Phase 2a proof-of-concept clinical studies in Myasthenia Gravis and Type 1 Diabetes, and other pipeline opportunities.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8025 Lamon Ave.
Skokie, IL 60077
USA
Phone
Undisclosed
Website
www.courpharma.com
Email Address
[email protected]
Overview
COUR Pharmaceuticals is developing ?rst-in-class therapies designed to reprogram the immune system to achieve antigen-speci?c tolerance for immune-mediated disease. COUR's platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression.
Profile
Cour Pharmaceuticals LinkedIn Company Profile
Social Media
Cour Pharmaceuticals Company Twitter Account
Company News
Cour Pharmaceuticals News
Facebook
Cour Pharmaceuticals on Facebook
YouTube
Cour Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
John Puisis
  John Puisis LinkedIn Profile  John Puisis Twitter Account  John Puisis News  John Puisis on Facebook
Chief Financial Officer
Brian Bock
  Brian Bock LinkedIn Profile  Brian Bock Twitter Account  Brian Bock News  Brian Bock on Facebook
VP - Finance
Nick Bortolotti
  Nick Bortolotti LinkedIn Profile  Nick Bortolotti Twitter Account  Nick Bortolotti News  Nick Bortolotti on Facebook
VP - General Counsel
Tracy Weiner
  Tracy Weiner LinkedIn Profile  Tracy Weiner Twitter Account  Tracy Weiner News  Tracy Weiner on Facebook
VP - Product Management
Michael Boyne
  Michael Boyne LinkedIn Profile  Michael Boyne Twitter Account  Michael Boyne News  Michael Boyne on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/30/2024: BBO Exchange venture capital transaction
Next: 1/30/2024: Enterprise Therapeutics venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to record all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.